CVAC - CureVac N.V.

4.66
-0.010   -0.215%

Share volume: 1,149,400
Last Updated: 01-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$4.67
-0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
-8.98%
6 Months
-13.54%
1 Year
47.47%
2 Year
38.69%
Key data
Stock price
$4.66
P/E Ratio 
0.00
DAY RANGE
$4.57 - $4.66
EPS 
N/A
52 WEEK RANGE
$2.48 - $5.72
52 WEEK CHANGE
$47.00
MARKET CAP 
702.983 M
YIELD 
N/A
SHARES OUTSTANDING 
223.880 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-22-2025
BETA 
1.21
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Franz-Werner Haas
Region: US
Website: curevac.com
Employees: 880
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CureVac N.V. focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA) It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV and CV7202. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma.

Recent news